Heparin Leo (Heparin Sodium)

Heparin Leo is employed in clinical settings where anticoagulation is required to reduce the risk of thrombus formation. It is commonly used in the following situations:

• Prevention of deep‑vein thrombosis (DVT) in postoperative or immobilized patients.
• Management of acute coronary syndromes, including unstable angina.
• Maintenance of catheter patency during hemodialysis or intravenous therapy.
• Treatment of pulmonary embolism as part of a broader anticoagulation regimen.
• As an adjunct during cardiac surgery to prevent clot formation on extracorporeal circuits.

Heparin Leo may cause a range of adverse reactions, varying from mild to severe. Awareness of these effects helps clinicians monitor patients appropriately.

Common

• Minor bleeding at injection site or from mucous membranes.
• Localized bruising or hematoma formation.
• Transient elevation of liver enzymes.
• Mild thrombocytopenia (platelet count reduction).
• Nausea or mild gastrointestinal discomfort.

Serious

• Major hemorrhage, including intracranial or gastrointestinal bleeding.
• Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Spontaneous spinal or epidural hematoma.
• Severe elevation of liver transaminases indicating hepatic injury.

When prescribing or administering Heparin Leo, several safety considerations should be observed to minimize risk:

• Verify baseline coagulation parameters (aPTT, PT/INR) before initiation.
• Adjust dose in patients with renal or hepatic impairment, as clearance may be altered.
• Avoid use in individuals with a known hypersensitivity to heparin or pork products.
• Monitor platelet counts regularly to detect heparin‑induced thrombocytopenia.
• Use caution in pregnant or breastfeeding patients; assess risk‑benefit ratio.
• Educate patients about signs of bleeding and advise immediate medical attention if they occur.
• Ensure proper storage conditions to maintain product stability.

Heparin Leo can interact with several other medications, influencing its anticoagulant effect or increasing bleeding risk.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without careful monitoring.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) or aspirin, which may potentiate bleeding.
• Thrombolytic agents such as alteplase or streptokinase.
• High‑dose corticosteroids that can affect platelet function.

Use with caution

• Antiplatelet agents (e.g., clopidogrel, ticagrelor) – monitor for additive bleeding.
• Selective serotonin reuptake inhibitors (SSRIs) – may increase gastrointestinal bleeding.
• Glycoprotein IIb/IIIa inhibitors – heightened risk of hemorrhage.
• Certain antibiotics (e.g., vancomycin) that can affect coagulation pathways.